Pharmacokinetics and Safety of a Single Dose and Multiple Doses of Allisartan Isoproxil, an Angiotensin II Receptor Blocker, in Healthy Chinese People.

MLA

Yi, Wu, et al. “Pharmacokinetics and Safety of a Single Dose and Multiple Doses of Allisartan Isoproxil, an Angiotensin II Receptor Blocker, in Healthy Chinese People.” Clinical Pharmacology in Drug Development, vol. 11, no. 1, Jan. 2022, pp. 43–50. EBSCOhost, https://doi.org/10.1002/cpdd.995.

APA

Yi, W., Yan, P., Lin, S., Hao, R., Wang, Y., Yu, J., Fang, L., Zhu, J., Zhao, D., Tong, S., Si, Y., Ye, T., Wu, Z., Qin, Z., Huang, H., Deng, C., Sun, J., & Wang, Y. (2022). Pharmacokinetics and Safety of a Single Dose and Multiple Doses of Allisartan Isoproxil, an Angiotensin II Receptor Blocker, in Healthy Chinese People. Clinical Pharmacology in Drug Development, 11(1), 43–50. https://doi.org/10.1002/cpdd.995

Chicago

Yi, Wu, Peiyuan Yan, Sisi Lin, Rui Hao, Yannan Wang, Jin Yu, Lu Fang, et al. 2022. “Pharmacokinetics and Safety of a Single Dose and Multiple Doses of Allisartan Isoproxil, an Angiotensin II Receptor Blocker, in Healthy Chinese People.” Clinical Pharmacology in Drug Development 11 (1): 43–50. doi:10.1002/cpdd.995.